Bausch Health/$BHC
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Bausch Health
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Ticker
$BHC
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Laval, Canada
Employees
20,700
ISIN
CA0717341071
Website
Bausch Health Metrics
BasicAdvanced
$2.6B
-
-$0.11
0.43
-
Price and volume
Market cap
$2.6B
Beta
0.43
52-week high
$9.49
52-week low
$3.96
Average daily volume
2.4M
Financial strength
Current ratio
1.347
Quick ratio
0.753
Long term debt to equity
-8,845
Total debt to equity
-6,782.298
Interest coverage (TTM)
1.36%
Profitability
EBITDA (TTM)
3,089
Gross margin (TTM)
70.78%
Net profit margin (TTM)
-0.41%
Operating margin (TTM)
19.08%
Effective tax rate (TTM)
142.86%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
4.31%
Return on equity (TTM)
39.13%
Valuation
Price to revenue (TTM)
0.27
Price to book
-2.05
Price to tangible book (TTM)
-0.15
Price to free cash flow (TTM)
2.159
Free cash flow yield (TTM)
46.32%
Free cash flow per share (TTM)
329.81%
Growth
Revenue change (TTM)
8.53%
Earnings per share change (TTM)
-91.18%
3-year revenue growth (CAGR)
5.34%
10-year revenue growth (CAGR)
1.38%
3-year earnings per share growth (CAGR)
-54.22%
10-year earnings per share growth (CAGR)
-27.95%
What the Analysts think about Bausch Health
Analyst ratings (Buy, Hold, Sell) for Bausch Health stock.
Bulls say / Bears say
Bausch Health's Salix segment reported a 9% year-over-year revenue increase in Q1 2025, indicating strong performance in its gastroenterology business. (Investing.com)
The company launched the Fraxel FTX™, an advanced skin resurfacing technology, at the ASLMS 2025 Conference, potentially expanding its aesthetic product portfolio. (StockTitan)
Bausch Health received Health Canada clearance for the Thermage FLX system, enhancing its presence in the non-invasive skin tightening market. (StockTitan)
Bausch Health reported a Q1 2025 loss per share of $0.17, missing analyst expectations of $0.69 EPS, raising concerns about profitability. (Investing.com)
The company has a high leverage ratio of approximately 7 times, with upcoming debt maturities in 2025-2026, posing solvency risks. (Markets Insider)
Bausch + Lomb initiated a voluntary recall of certain intraocular lenses due to reported complications, potentially impacting brand reputation and financial performance. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Bausch Health Financial Performance
Revenues and expenses
Bausch Health Earnings Performance
Company profitability
Bausch Health News
AllArticlesVideos
Bausch Health to Announce Second Quarter 2025 Results on July 30
Accesswire·2 days ago
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility
Business Wire·1 week ago
Five Popular Stocks Insiders Have Been Aggressively Buying
24/7 Wall Street·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bausch Health stock?
Bausch Health (BHC) has a market cap of $2.6B as of July 04, 2025.
What is the P/E ratio for Bausch Health stock?
The price to earnings (P/E) ratio for Bausch Health (BHC) stock is 0 as of July 04, 2025.
Does Bausch Health stock pay dividends?
No, Bausch Health (BHC) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Bausch Health dividend payment date?
Bausch Health (BHC) stock does not pay dividends to its shareholders.
What is the beta indicator for Bausch Health?
Bausch Health (BHC) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.